Cellbxhealth Plc · LSE:CLBX
Cellbxhealth — ANGLE — H1 2017 Earnings Presentation
15 slides from Cellbxhealth's earnings presentation, Jan 26, 2017
Slide 1: Parsortix Liquid Biopsy Interim Results for the six months ended 31 October 2016
Parsortix Liquid Biopsy Interim Results for the six months ended 31 October 2016 Andrew Newland and Ian Griffiths 26 January 2017 © ANGLE plc 2017 Page 1
Slide 2: Legal disclaimer
Legal disclaimer LSE AIM: AGL OTCQX: ANPCY This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The information and opinions contained in this presentation have not been indepen
Slide 3: Highlights
Highlights Liquid Biopsy Ovarian clinical studies initiated in Europe and Post period end United States Barts present prostate cancer results FDA clinical studies submitted to 3 world class US cancer centres and analytical study in progress Positive interim evaluation of ovarian cancer clinical stud
Slide 4: Financial Results for the six months ended October 2016
Financial Results for the six months ended 31 October 2016 Six months ended 31 October 2016 2015 Statement of Comprehensive Income £’000 £’000 Revenue 219 0 Cost of sales (43) Comments 0 Gross profit 176 0 Research use sales established and Operating costs (3,088) growing (2,399) Other income 20 12
Slide 5: Liquid biopsy improving healthcare and reducing costs: driving precision medicine
Liquid biopsy improving healthcare and reducing costs: driving precision medicine Cancer Research UK: “One in two people born after 1960 in the UK will be diagnosed with some form of cancer during their lifetime.” Each patient’s cancer is different Big pharma developing more selective drugs: Patient
Slide 6: ANGLE differentiation
ANGLE differentiation The Complete Picture Intact CTCs not just ctDNA. Compatible with all downstream analysis techniques Evidence-based driven by KOLs and clinical studies Patented product solution Overcomes problems with service labs Scaleable business with third party manufacture Page 6 © ANGLE p
Slide 7: Benefits of Parsortix CTCs – the Complete Picture
Benefits of Parsortix CTCs – the Complete Picture 1. CTCs are live cancer cells circulating in the blood known as circulating tumour cells 2. cfDNA also known as ctDNA is cell-free circulating fragments of DNA from dead cells, which may be found in the plasma component of the blood © ANGLE plc 2017
Slide 8: Far-reaching market potential
Far-reaching market potential Evidence-based approach to prove performance with ovarian cancer, FDA breast cancer Substantiating value as sample collection platform Emerging $ multi-billion market (Goldman Sachs $14bn in US alone by 2025) Partnering strategy for widespread deployment © ANGLE plc 201
Slide 9: Growing research use sales
Growing research use sales First sales achieved FY16 Targeting sales to leading cancer centres − broaden range of users of the system with additional posters, publications and clinical evidence Sales pipeline increasing − new clinical applications and companion diagnostics Cancer Research UK contrac
Slide 10: Ovarian cancer clinical application in development
Ovarian cancer clinical application in development Ovarian sales potential >£300m p.a. Medical University of Vienna 65 100% 100% In US, 200,000 women p.a. have surgery on abnormal pelvic masses 95% 92% ParsortixTM test to triage patients to Local Specialist 90% target identify appropriate treatment
Slide 11: Ovarian cancer clinical studies
Ovarian cancer clinical studies 200 patient European study (ANG-001) European study >95% patient enrolled, due to − Medical University of Vienna, Charité and Vivantes complete enrolment in February 2017 200 patient United States study (ANG-003) US Study 70% patient enrolled, due to complete − Univer
Slide 12: FDA authorisation progress
FDA authorisation progress Potential to be first FDA cleared system for ANG-002 clinical study plan developed in harvesting cancer cells from blood consultation with three world-class US breast cancer centres Success will position Parsortix as the gold − designed to meet FDA remaining requirements s
Slide 13: Other key areas of development
Other key areas of development Breast cancer blood test alternative to invasive metastatic biopsy (RNA) − successful pilot study by University of Southern California − FDA study being extended to cover this form of analysis − clinical data expected in CY17 Prostate cancer blood test alternative to p
Slide 14: Summary
Summary Liquid biopsy ParsortixTM patented system seeking a leading position in emerging $ multi-billion liquid biopsy market Providing the Complete Picture (intact CTCs not just ctDNA) Ovarian cancer clinical studies headline data due Q2, CY17 FDA study to support metastatic breast cancer clearance
Slide 15: ANGLE plc
ANGLE plc ANGLE Europe Ltd ANGLE North America Inc 3 Frederick Sanger Road 3711 Market Street The Surrey Research Park University Science Center 8th floor Guildford GU2 7YD Philadelphia PA 19104 United Kingdom USA Website: www.ANGLEplc.com © ANGLE plc 2017 Page 15